Skip to content

K-Dense-AI/scientific-agent-skills / skills/pkpd-modeling

pkpd-modeling

Verified

Pharmacokinetic and pharmacodynamic modelling and simulation - non-compartmental analysis, compartmental and population PK, PK/PD and exposure-response, TMDD, PBPK orientation, bioequivalence, allometric scaling and first-in-human dose, drug interaction prediction, and Bayesian therapeutic drug monitoring. Use when analysing concentration-time data, deriving exposure metrics, fitting PK or PD models, or evaluating dosing regimens. Triggers include "pharmacokinetics", "pharmacodynamics", "PK/PD", "NCA", "non-compartmental", "AUC", "Cmax", "lambda z", "half-life", "clearance", "volume of distribution", "compartmental model", "population PK", "popPK", "NONMEM", "nlmixr2", "Pharmpy", "Monolix", "exposure-response", "Emax", "EC50", "indirect response", "effect compartment", "TMDD", "PBPK", "bioequivalence", "RSABE", "ABEL", "allometric scaling", "first-in-human", "MABEL", "drug-drug interaction", "DDI", "ICH M12", "concentration-QTc", "therapeutic drug monitoring", "MIPD", and "dosing regimen".

references/pbpk.md

View on GitHub
# PBPK: context of use and verification

PBPK links physiology, drug properties and mechanistic disposition. System parameters can be
fixed, population-distributed, calibrated or uncertain; they are not inherently known. Use it when
the intended extrapolation benefits from mechanisms such as enzyme/transporter DDI, absorption,
organ function, maturation or tissue distribution. Population PK and PBPK can complement each
other; neither is automatically superior for every in-range or out-of-range question.

## Platforms

PK-Sim/MoBi in Open Systems Pharmacology Suite 12 Update 3 (PK-Sim/MoBi 12.3) provide an open
platform with an R interface. Vendor suites include Simcyp and GastroPlus. Select according to
required mechanisms, population/model availability, qualification evidence and reproducibility;
no platform name alone establishes regulatory acceptance. The current `ospsuite` 12.3.2 release
notes should be checked for matching runtime and platform requirements before installation.
[OSP releases](https://github.com/Open-Systems-Pharmacology/Suite/releases),
[OSPSuite-R news](https://github.com/Open-Systems-Pharmacology/OSPSuite-R/blob/main/NEWS.md).
These platforms and interfaces were documentation-reviewed, not run in this refresh.

## Construction checks

1. Specify blood/plasma basis, unbound fractions, amount/concentration units, organ volumes/flows,
   partition model and elimination routes. Do not mix plasma fu and whole-blood clearance without
   the blood/plasma conversion.
2. For perfusion-limited distribution, use a consistent partition basis in
   `Vt*dCt/dt=Qt*(Ca-Ct/Kt)`. Permeability-limited systems need separate vascular/extravascular
   states and transfer terms; a tissue name alone does not choose the correct approximation.
3. Scale intrinsic clearance with traceable protein/cell abundance and organ-size inputs.
   Well-stirred hepatic blood clearance is `Qh*fu_b*CLint/(Qh+fu_b*CLint)` under its assumptions.
4. Distinguish measured, predicted, fixed and fitted parameters. Tissue partition methods and
   empirical IVIVE scaling factors are modeling choices, not direct observations.
5. Check mass balance, numerical tolerance, dose/input events and sensitivity to uncertain binding,
   fm, Ki, CLint, permeability and physiological inputs.

## Credibility for the intended decision

Separate calibration data from verification evidence where feasible. Evaluate relevant routes,
doses, temporal profiles and challenging conditions; agreement with one AUC does not validate a
mechanism. For DDI, interrogate both perpetrator and substrate components and alternatives.
Predicted tissue exposure can remain uncertain despite agreement with plasma concentrations.

There is no universal twofold acceptance rule. Prespecify context-appropriate criteria and quantify
parameter, structural and population uncertainty. An organ-impairment prediction does not
automatically replace a clinical study. Explain why verification supports the specific extrapolation.
[ICH M15 FDA guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m15-general-principles-model-informed-drug-development)
and [ICH M12](https://www.ema.europa.eu/en/scientific-guidelines/ich-m12-drug-interaction-studies)
provide relevant decision frameworks.

Archive the model, software/library versions, population definition, calibration/verification data,
parameter sources, sensitivity design and simulation seeds. The bundled one-to-three-compartment
models are empirical PK, not PBPK implementations.
slack-gif-creatoranthropics/skillsKnowledge and utilities for creating animated GIFs optimized for Slack. Provides constraints, validation tools, and animation concepts. Use when users request animated GIFs for Slack like "make me a GIF of X doing Y for Slack."Stars: 198kUpdated Claude CodeCodexVerifiedInstall
ponytailDietrichGebert/ponytailLazy senior dev mode for any coding task: the smallest change that fully solves it, and a reply a busy human understands in one read.Stars: 194kUpdated Claude CodeCodexVerifiedInstall
ponytail-debtDietrichGebert/ponytailHarvest every shortcut: comment into one debt ledger, so deferrals get tracked instead of forgotten. One-shot report.Stars: 194kUpdated Claude CodeCodexVerifiedInstall
ponytail-debtDietrichGebert/ponytailList every `shortcut:` comment (and older `ponytail:` ones) as a debt ledger. One-shot report, changes nothing. Use for "ponytail debt", "what did ponytail defer", "list the shortcuts", /ponytail-debt.Stars: 194kUpdated Claude CodeCodexVerifiedInstall